

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

## EQA round: E23/19 - Hormones 2

Dead line: 06.08.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(193) Ferritin</b>					8							8	7	88%
Samples and groups	[µg/L]													
<b>Sample A</b>		329	26	7,7	8							8	8	100%
Other					8	0						8		
							1x 4/1, 3x 4/60, 3x 4/179, 1x 6/60							
<b>Sample B</b>		94,9	5,9	6,2	8							8	7	88%
Other					8	0						8		
							1x 4/1, 3x 4/60, 3x 4/179, 1x 6/60							
<b>(320) LH</b>					7							7	7	100%
Samples and groups	[U/L]													
<b>Sample A</b>		47,9	11	22	7							7	7	100%
Other					7	0						7		
							2x 4/1, 2x 4/12, 3x 4/60							
<b>Sample B</b>		78,4	15	19	7							7	7	100%
Other					7	0						7		
							2x 4/1, 2x 4/12, 3x 4/60							
<b>(321) FSH</b>					7							7	6	86%
Samples and groups	[U/L]													
<b>Sample A</b>		7,07	0,80	11	7							7	6	86%
Other					7	0						7		
							2x 4/1, 2x 4/12, 3x 4/60							
<b>Sample B</b>		4,91	0,34	6,9	7							7	6	86%
Other					7	0						7		
							2x 4/1, 2x 4/12, 3x 4/60							
<b>(322) Prolactin</b>					7							7	7	100%
Samples and groups	[mU/L]													
<b>Sample A</b>		721	55	7,6	7							7	7	100%
Other					7	0						7		
							2x 4/1, 1x 4/12, 2x 4/60, 2x 4/179							
<b>Sample B</b>		566	48	8,4	7							7	7	100%
Other					7	0						7		
							2x 4/1, 1x 4/12, 2x 4/60, 2x 4/179							
<b>(325) Insulin</b>					5							5	5	100%
Samples and groups	[mU/L]													
<b>Sample A</b>		116	26	22	5							5	5	100%
Other					5	0						5		
							1x 4/1, 1x 4/12, 1x 4/60, 2x 4/179							
<b>Sample B</b>		38,9	7,7	20	5							5	5	100%
Other					5	0						5		
							1x 4/1, 1x 4/12, 1x 4/60, 2x 4/179							
<b>(326) Folate</b>					9							9	8	89%
Samples and groups	[nmol/L]													
<b>Sample A</b>		35,2	6,1	17	9							9	9	100%
Other					9	0						9		
							2x 4/1, 1x 4/12, 4x 4/60, 2x 4/179							
<b>Sample B</b>		15,8	4,0	25	9							9	8	89%
Other					9	0						9		
							2x 4/1, 1x 4/12, 4x 4/60, 2x 4/179							
<b>(327) Vitamin B12</b>					9							9	9	100%
Samples and groups	[pmol/L]													
<b>Sample A</b>		727	97	13	9							9	9	100%
Other					9	0						9		
							2x 4/1, 1x 4/12, 4x 4/60, 2x 4/179							
<b>Sample B</b>		535	67	12	9							9	9	100%
Other					9	0						9		
							2x 4/1, 1x 4/12, 4x 4/60, 2x 4/179							
<b>(328) hGH</b>					2							2	2	100%
Samples and groups	[mU/L]													
<b>Sample A</b>		39,3	1,5	3,8	2							2	2	100%
Other					2	0						2		
							2x 4/29							
<b>Sample B</b>		15,9	0,19	1,2	2							2	2	100%
Other					2	0						2		
							2x 4/29							
<b>(329) IGF-1</b>					3							3	3	100%
Samples and groups	[µg/L]													
<b>Sample A</b>		268	29	11	3							3	3	100%

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

## EQA round: E23/19 - Hormones 2

Dead line: 06.08.2019

Test	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability							
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(329) IGF-1</b>					3							3	3	100%
Samples and groups	[µg/L]													
<b>Sample A</b>		268	29	11	3							3	3	100%
Other					3	0						3		
							2x 4/29, 1x 4/60							
<b>Sample B</b>		493	170	34	3							3	3	100%
Other					3	0						3		
							2x 4/29, 1x 4/60							
<b>(390) Renin</b>					3							2	1	50%
Samples and groups	[ng/L]													
<b>Sample A</b>		28,3	8,4	30	3							2	1	50%
Other					3	0						2		
							1x 2/66, 2x 4/164							
<b>Sample B</b>		28,4	8,9	31	3							2	2	100%
Other					3	0						2		
							1x 2/66, 2x 4/164							
<b>(393) C-peptide</b>					7							7	6	86%
Samples and groups	[pmol/L]													
<b>Sample A</b>		255	62	24	7							7	7	100%
Other					7	0						7		
							2x 4/1, 3x 4/60, 2x 4/179							
<b>Sample B</b>		269	51	19	7							7	6	86%
Other					7	0						7		
							2x 4/1, 3x 4/60, 2x 4/179							
<b>(394) SHBG</b>					5							5	5	100%
Samples and groups	[nmol/L]													
<b>Sample A</b>		30,8	0,25	0,82	5							5	5	100%
Other					5	0						5		
							1x 4/1, 4x 4/60							
<b>Sample B</b>		30,7	1,3	4,2	5							5	5	100%
Other					5	0						5		
							1x 4/1, 4x 4/60							
<b>(405) Parathyroid hormone (PTH)</b>					7							7	6	86%
Samples and groups	[pmol/L]													
<b>Sample A</b>		9,03	1,6	17	7							7	6	86%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		8,11	0,19	2,4	5	0	CVPG	7,99	0,092	23%	6,15	9,83	5	
Other					2	0						2		
							1x 4/1, 1x 4/12							
<b>Sample B</b>		17,2	3,2	18	7							7	6	86%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		15,4	0,46	3,0	5	0	CVPG	15,5	0,17	23%	11,9	19,1	5	
Other					2	0						2		
							1x 4/1, 1x 4/12							

st\_kn\_p

End of report

Printed: 14.08.2019